Investigation Launched by Pomerantz Law Firm for Investors of RxSight, Inc. - RXST

Investor Alert: Pomerantz Law Firm Investigates RxSight, Inc. Claims

Introduction
Pomerantz LLP, a renowned law firm specializing in corporate litigation, has launched an investigation concerning RxSight, Inc. (NASDAQ: RXST) and is reaching out to investors. The inquiry centers on potential securities fraud allegations and other unlawful practices that may have affected the company’s financial standing and its shareholders.

Background on RxSight, Inc.
RxSight, a company focused on developing innovative vision correction solutions, has seen substantial fluctuations in its market performance recently. The investigation is timely, given the unsettling news that surfaced during late December 2025. On December 22, the company announced the departure of its Chief Financial Officer, Shelley Thunen, who would vacate her position but remain with the company until her successor is appointed or until January 31, 2026.

Industry experts, including analysts from BTIG, expressed surprise at this development, especially as there had been emerging signs of operational improvement. This departure followed a prior management reshuffle earlier in the month, signaling potential ongoing challenges within the company’s leadership that could hinder a broader recovery planned into 2026.

The Impact on Stock Price
The announcement of Thunen’s exit had a notable negative impact on RxSight's stock, with prices dropping by $1.22, which is approximately 9.98%, closing at $11.01 per share on December 23, 2025. This dramatic fall raised alarms among investors, prompting the investigation from Pomerantz LLP regarding possible misconduct related to the recent executive turnover.

What This Means for Investors
For shareholders and investors of RxSight, this investigation could be crucial. If findings suggest that the company or its executives engaged in misleading practices or failed to disclose critical operational challenges, affected investors might be entitled to compensation through class action lawsuits. Pomerantz law firm advises those impacted to reach out and participate in the investigation to better understand their rights and potential recourse.

Joining the Class Action
Those interested in joining the class action against RxSight are encouraged to contact Danielle Peyton at Pomerantz LLP for further guidance. The firm is known for its relentless fight on behalf of victims of corporate misconduct, having significant expertise in handling such cases effectively over its 85-year history.

Conclusion
The ongoing scrutiny of RxSight, Inc. serves as a reminder of the challenges within the corporate sector, particularly when it comes to transparency and the responsibilities held by executives. Investors must stay alert to protect their rights and financial interests, especially in the face of potentially tumultuous corporate environments. Proper legal advice and representation could prove essential during such uncertain times.

For those affected, it is vital to remain informed about the developments of this investigation and potential legal avenues available to them to recover any losses incurred as a result of suspected securities fraud.